MATISSE PHARMACEUTICALS
Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 for the treatment of severe sepsis and septic shock.
MATISSE PHARMACEUTICALS
Industry:
Biopharma Biotechnology Life Science
Founded:
2014-01-01
Address:
Geleen, Limburg, The Netherlands
Country:
The Netherlands
Website Url:
http://www.matisse-pharma.com
Total Employee:
1+
Status:
Active
Contact:
+31 (0)88 2554 070
Email Addresses:
[email protected]
Total Funding:
1.9 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Content Delivery Network Euro Pound Sterling Japanese Yen Wix
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Axichem
Axichem is an biotechnology company specializing in development of natural analogue ingredients.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Materiomics BV
Materiomics BV is a biotech company located in Enschede, The Netherlands.
Current Advisors List
Current Employees Featured
Investors List
Chemelot Ventures
Chemelot Ventures investment in Venture Round - Matisse Pharmaceuticals
Limburg Business Development Fund (LBDF)
Limburg Business Development Fund (LBDF) investment in Venture Round - Matisse Pharmaceuticals
Official Site Inspections
http://www.matisse-pharma.com
- Host name: webhosting.transip.nl
- IP address: 86.105.244.1
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Matisse Pharmaceuticals"
Who we are - Matisse pharmaceuticals
Matisse Pharmaceuticals is based at the Brightlands Chemelot Campus in Geleen, The Netherlands. Mission, vision and values. Company Matisse Pharmaceuticals B.V. …See details»
Matisse pharmaceuticals | Saving millions of lives by …
Matisse pharmaceuticals is developing the first life-saving treatment targeting the root cause of sepsis. About us. Matisse Pharmaceuticals BV is a biopharmaceutical clinical stage company developing a product portfolio of …See details»
Management board - Matisse pharmaceuticals
Kees Groen is co-founder and CEO of DGr Pharma and was founder and from 1997 until 2015 General Manager of Kinesis Pharma, a consultancy company in drug development. He was also co-founder and CEO of LAP&P Consultants, …See details»
Matisse Pharmaceuticals - Crunchbase Company …
Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with …See details»
Matisse Pharmaceuticals B.V. - LinkedIn
Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main ...See details»
Matisse Pharmaceuticals raises financing for its phase …
Apr 3, 2020 Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main development …See details»
Matisse Pharmaceuticals meets primary objectives in study with …
Jan 30, 2024 About Matisse Pharmaceuticals. Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing …See details»
Mission, vision and values | Matisse pharmaceuticals
We believe quality is a continuous process involving everyone in the organization. We aim for the highest quality standards in development, production and distribution. Additionally we give …See details»
Matisse Pharmaceuticals - Products, Competitors, Financials, …
Matisse Pharmaceuticals is a clinical stage biopharmaceutical company working on therapies for diseases characterized by elevated levels of extracellular cytotoxic histones, such as sepsis …See details»
Matisse Pharmaceuticals BV: Drug pipelines, Patents, Clinical trials ...
Explore Matisse Pharmaceuticals BV with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Infectious Diseases, Technology Platform:Unknown, Drug:M …See details»
Matisse Pharmaceuticals | Startup Profile and Investments
Matisse Pharmaceuticals is a biotechnology firm founded in 2014 with a focus on developing pioneering therapies for severe inflammatory disorders such as sepsis. The company slogan, …See details»
Matisse Pharmaceuticals - Brightlands Venture Partners
Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation …See details»
Matisse Pharmaceuticals closes EUR 3.6 million financing round
Jan 4, 2024 Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the …See details»
Matisse Pharmaceuticals - Craft
Matisse Pharmaceuticals is a biotechnology company dedicated to the development of pharmaceutical therapies. It is used to treat disorders that are associated with fulminant …See details»
Supervisory board - Matisse pharmaceuticals
Georges has joined the Matisse Supervisory board in 2020. Georges de Meris is an independent advisor and supervisor and holds multiple board positions at healthcare companies and non …See details»
Matisse Pharmaceuticals receives approval from the Dutch Health ...
Geleen, The Netherlands, 10 November 2021. Matisse Pharmaceuticals B.V., a clinical stage company developing the medicinal product M6229 for the treatment of sepsis, announced …See details»
Matisse Pharmaceuticals - Overview, News & Competitors
Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its …See details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 In response, pharma leaders have begun exploring fundamental changes to their capabilities, talent, and processes. ... Thirty-seven of them expect their organization to pursue …See details»
Partnering - Matisse pharmaceuticals
Matisse Pharmaceuticals BV has obtained a worldwide exclusive and transferable license from Maastricht University (MU) and Maastricht University Medical Centre ... Basic Pharma. For the …See details»
Matisse Pharmaceuticals closes EUR 3.6 million financing round
In the course of 2024, Matisse aims to conclude a series A funding round which should cover the full execution of the mentioned phase II clinical trial, the scale up of production to a …See details»